Saturday, October 3, 2026

Platinum Bullish Momentum: 0.92% Up Since The Last Session

ViaNews Editorial Team

January 8, 2021

Platinum Bullish Momentum: 0.92% Up Since The Last Session

Platinum is currently on bullish momentum. At 21:08 EST on Thursday, 7 January, Platinum is at $1,135.00 and 0.92% up since the last session's close.

Platinum Range

Platinum is 0.799% up from its last session low of $1,126.00 and 0.451% up from its last session high of $1,129.90.

Platinum is 0.45% up from its last three sessions higher value of $1,129.90 and is 2.47% up from its last three sessions lower value of $1,107.60.

Platinum is 0.45% up from its last seven sessions higher value of $1,129.90 and is 6.09% up from its last seven sessions lower value of $1,069.80.

Platinum is 0.45% up from its last month's higher value of $1,129.90 and is 12.88% up from its last month's lower value of $1,005.50.

Volatility

Platinum's last day, last week, and last month's average volatility was 2.01%, 1.72%, and 0.96%, respectively.

Platinum's last day, last week, and last month's high and low average amplitude percentage was 0.35%, 0.75%, and 0.66%, respectively.

Last news about Platinum

Amex revamps platinum perks again in bid to retain customers. According to Bloomberg Quint on Tuesday, 5 January, "The company will offer as much as $180 in credits for purchases made through PayPal with the $550-a-year consumer Platinum card, and up to $1,700 in credits for virtual personal training with luxury-gym chain Equinox, car rentals with Avis Budget Group Inc., purchases on Home Depot Inc.'s website and spending with other retailers.", "American Express Co. will once again add perks to its popular Platinum cards to avoid losing customers as the pandemic continues to curtail spending on the firm's cards."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com